Browsing by Author "Valdes-Chavarri, Mariano (57216641409)"
Now showing 1 - 1 of 1
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Randomised evaluation of a novel biodegradable polymer-based sirolimus-eluting stent in ST-segment elevation myocardial infarction: The MASTER study(2019) ;Valdes-Chavarri, Mariano (57216641409) ;Kedev, Sasko (23970691700) ;Neskovic, Aleksandar N. (35597744900) ;de la Tassa, Cesar Morís (57222430348) ;Zivkovic, Milan (57535325700) ;Nouche, Ramiro Trillo (6506199560) ;González, Nicolas Vázquez (56152454100) ;Bartorelli, Antonio L. (7005844246) ;Antoniucci, David (7005655782) ;Tamburino, Corrado (57212260375) ;Colombo, Antonio (35354455800) ;Abizaid, Alexandre (36122299200) ;McFadden, Eugene (55510816600) ;García-García, Hector M. (9633803100) ;Milasinovic, Dejan (24823024500)Stankovic, Goran (59150945500)Aims: The MASTER study was designed to compare the performance of a new biodegradable polymer sirolimus-eluting stent (BP-SES) with a bare metal stent (BMS) in patients with ST-segment elevation myocardial infarction (STEMI). Methods and results: The study was a prospective, randomised (3:1), controlled, single-blind multicentre trial that enrolled 500 STEMI patients within 24 hours of symptom onset during 2013-2015. Three hundred and seventy-five patients were treated with BP-SES and 125 with BMS. One hundred and four (104) randomised patients underwent angiographic follow-up at six months. The primary clinical endpoint was target vessel failure (TVF), defined as cardiac death, MI not clearly attributable to a non-target vessel, or clinically driven target vessel revascularisation (TVR) at 12 months. The primary angiographic endpoint was in-stent late lumen loss (LLL) at six months in the angiographic cohort. The major secondary endpoint for safety was a composite of all-cause death, recurrent MI, unplanned infarct-related artery revascularisation, stroke, definite stent thrombosis (ST) or major bleeding at one month. At 12 months, TVF had occurred in 6.1% of BP-SES and 14.4% of BMS patients (pnon-inferiority=0.0004), mainly driven by a higher rate of repeat revascularisation in BMS patients. The safety endpoint occurred in 3.5% of BP-SES and 7.2% of BMS patients (p=0.127). In-stent LLL demonstrated the superiority (p=0.0125) of BP-SES (0.09±0.43 mm) over BMS (0.79±0.67 mm). Conclusions: The study showed clinical non-inferiority and angiographic superiority of BP-SES versus a comparator BMS, suggesting that this novel DES may be a potential treatment option in STEMI. © Europa Digital & Publishing 2019. All rights reserved.
